4.145
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - ulpravda.ru
Moleculin Biotech regains Nasdaq listing compliance - MarketScreener
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView — Track All Markets
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - ulpravda.ru
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Why Moleculin Biotech Inc. (MOL) stock is listed among top recommendationsJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Earnings Report: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Market Review: Why Moleculin Biotech Inc. stock could rally in 2025July 2025 Snapshot & Fast Gain Swing Alerts - DonanımHaber
What technical charts say about Moleculin Biotech Inc. stockMarket Risk Analysis & Smart Swing Trading Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock could rally in 2025Global Markets & Verified Momentum Stock Watchlist - DonanımHaber
Aug Wrap: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Why Moleculin Biotech Inc. stock is popular among millennialsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
Why hedge funds are buying Moleculin Biotech Inc. stockTrade Risk Summary & Accurate Trade Setup Notifications - ulpravda.ru
Moleculin Biotech reports positive phase 1 trial results - MSN
Moleculin Biotech stock falls after pediatric brain tumor trial results By Investing.com - Investing.com Australia
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com Nigeria
Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech regains Nasdaq compliance - MSN
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks
大文字化:
|
ボリューム (24 時間):